Stand Up To Cancer will receive a $4 million grant from Mirati Therapeutics Inc. to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst program.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
